UCB Group Soars as U.S. Clears Key Arthritis Drug

Bookmark and Share

Reuters -- Belgian pharmaceutical group received a major boost on Thursday when U.S. regulators approved its drug Cimzia for the treatment of rheumatoid arthritis, sending the stock 18 percent higher.

MORE ON THIS TOPIC